A study by Brown et al. demonstrated the feasibility of this approach using IL13Rα2-targeted CD8+ T cells to treat recurrent GBM, laying the groundwork for a new generation of locoregional delivery strategies [127]. This evidence concerns the gene CD8A and glioblastoma.